Johnson & Johnson Q4 Earnings: Cancer Drugs Performance Drives Revenue Beat, Issues Strong FY25 Outlook
Johnson & Johnson · PHARMACEUTICAL PREPARATIONS · Now $223.51
-2.0% in 7d after detection
Post-detection moves
1h
—
1d
-0.3%
3d
+1.9%
7d
-2.0%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS